Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Stock Has Average Target Price of $28.38

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given a consensus rating of “Hold” by the seven research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $28.38.

A number of analysts recently issued reports on KMTS shares. Piper Sandler reiterated an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 target price for the company. Royal Bank Of Canada set a $30.00 target price on Kestra Medical Technologies in a report on Tuesday, September 15th. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, July 15th.

Kestra Medical Technologies Trading Down 2.7%

KMTS stock opened at $25.77 on Friday. The company has a market capitalization of $1.53 billion, a PE ratio of -9.65 and a beta of 0.51. Kestra Medical Technologies has a 12 month low of $17.34 and a 12 month high of $30.00. The firm’s 50-day moving average is $26.13 and its 200 day moving average is $23.25. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The company had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. On average, research analysts anticipate that Kestra Medical Technologies will post -2.45 EPS for the current year.

Insider Transactions at Kestra Medical Technologies

In other news, insider Brian Webster sold 51,900 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the sale, the insider directly owned 475,215 shares in the company, valued at approximately $11,652,271.80. This trade represents a 9.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vaseem Mahboob sold 26,287 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $25.88, for a total transaction of $680,307.56. Following the transaction, the chief financial officer owned 60,609 shares of the company’s stock, valued at approximately $1,568,560.92. This trade represents a 30.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 246,928 shares of company stock worth $5,997,473. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Large investors have recently made changes to their positions in the business. Corient Private Wealth LP grew its stake in shares of Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after acquiring an additional 44,839 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after purchasing an additional 7,844 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after purchasing an additional 5,731 shares during the last quarter. Quantinno Capital Management LP acquired a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $431,000. Finally, Sei Investments Co. grew its position in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares during the last quarter.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies designed to help protect patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, or WCD, which is intended to provide temporary protection for patients who may be at elevated risk of life-threatening ventricular arrhythmias.

The ASSURE system continuously monitors a patient’s heart rhythm and is designed to detect potentially dangerous arrhythmias, including ventricular tachycardia and ventricular fibrillation.